Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual ...
Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator - Dose-dependent reduction in circulating lymphocytes - - Rapid lymphocyte recovery after cessation of dosing - - Phase 2 study in ulcerative colitis patients in 4Q 2020 …